What Moderna actually looks for
Moderna, headquartered in Cambridge, Massachusetts, built its identity around mRNA as a platform technology rather than a single drug, an idea the company has described as treating mRNA like a programmable operating system for the body. That platform bet paid off fastest with Spikevax, its COVID-19 vaccine developed at record speed with support from Operation Warp Speed and BARDA funding, but Moderna's leadership, including CEO Stephane Bancel, has pushed hard to show the platform extends well beyond COVID, into RSV (its approved vaccine mRESVIA), personalized cancer vaccines developed with Merck, and flu vaccine candidates. Interviewers expect candidates, especially in R&D and platform roles, to understand this pipeline breadth, since Moderna wants to be judged as a long-term biotech platform company, not a one-vaccine pandemic story. Because Moderna scaled from a research-stage biotech to a commercial manufacturer almost overnight during the pandemic, expect questions about operating in fast-growth, high-ambiguity environments.
Common questions and how to answer them
How do you think about Moderna's mRNA platform extending beyond COVID vaccines? Show awareness of the RSV vaccine mRESVIA and the personalized cancer vaccine program with Merck as evidence the platform generalizes, rather than treating Moderna as a single-product company. Describe a time you had to operate with incomplete information under serious time pressure. This maps directly to Moderna's pandemic-era scale-up, where clinical, manufacturing, and regulatory work happened in parallel rather than sequentially; use a real example of parallel-tracking decisions. How would you communicate scientific uncertainty to a non-scientific audience? Relevant given the public scrutiny mRNA vaccines received; answer with a concrete example of translating technical nuance without overstating certainty. In each case, connect your answer back to Moderna's platform thesis, that mRNA technology generalizes well beyond a single vaccine, since this is the throughline interviewers are listening for.
How to prepare
Read about Moderna's pipeline beyond COVID, specifically mRESVIA for RSV and the individualized neoantigen therapy program with Merck for melanoma, since interviewers want evidence you see Moderna as a platform company. Understand the basic mechanism of mRNA vaccines, how they instruct cells to produce a protein that triggers an immune response, well enough to explain it simply, since clear scientific communication is core to many roles here. If you're in a business or commercial role, know how Moderna's revenue and stock performance shifted as COVID vaccine demand declined, since this shapes current strategic priorities. Expect scientific and technical roles to include a presentation or deep-dive round where you defend your reasoning under detailed questioning, since Moderna's R&D culture prizes rigorous, evidence-based thinking.